Drug Profile

Zimberelimab - Arcus Biosciences/Guangzhou Gloria Biosciences/Taiho Pharmaceutical

Alternative Names: AB 122; GLS 010; GS-0122; WBP 3055; YUTUO

Latest Information Update: 15 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator WuXi Biologics
Developer Arcus Biosciences; Gilead Sciences; Guangzhou Gloria Biosciences; Memorial Sloan-Kettering Cancer Center; Strata Oncology; Taiho Pharmaceutical; UCLAs Jonsson Comprehensive Cancer Center; University of Texas Southwestern Medical Center; Yale University
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Marketed Cervical cancer; Hodgkin's disease
Phase III Gastrointestinal cancer; Non-small cell lung cancer
Phase II Biliary cancer; Liposarcoma; Liver cancer; Malignant melanoma; Rectal cancer
Phase I/II Colorectal cancer; Pancreatic cancer; Solid tumours
No development reported Cancer; Glioblastoma
Discontinued Prostate cancer

12 Oct 2025 Updated efficacy and adverse events data from the phase II EDGE-Gastric trial in Gastrointestinal cancer released by Gilead Sciences and Arcus Biosciences
09 Jul 2025 Arcus Biosciences completes a phase II ARC-7 trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Monotherapy, Metastatic disease, First-line therapy) in Canada, Australia, Singapore, South Korea, Hong Kong, Taiwan, US (IV) (NCT04262856 (700316154)
23 Jan 2025 Efficacy and adverse events data from phase I trial in Oesophageal cancer presented at the Gastrointestinal Cancers Symposium (ASCO-GI-2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com